Why Is AstraZeneca PLC Down Today?
AstraZeneca PLC (LSE:AZN) shares eased 1.05% to 13,886.0p today. The movement is modest and comes after a results update on 30 October in which the company reported continued growth in Revenue and earnings.
For the nine months to 30 September 2026, total revenue rose 7% at constant exchange rates to $46.9 billion, and Core Earnings per share increased 14% to $8.00. In the third quarter alone, total revenue was $16.2 billion, up 7%, and Core Earnings Per Share were $2.79, up 19% at constant exchange rates.
Large pharmaceutical shares often move with wider healthcare sentiment, so a small change on a single day does not alter the underlying picture.
About AstraZeneca PLC
AstraZeneca PLC is a global, science-led biopharmaceutical company that discovers, develops and sells prescription medicines. Its main therapy areas include oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare disease.
The group is headquartered in Cambridge in the UK and operates across a wide range of regions. Its scale and diversity are why LSE:AZN is one of the most widely followed names in the UK market.
Key Reasons Behind the Move Today
Pharmaceutical shares are influenced by clinical trial news, regulatory decisions, currency movements and sector rotation. After a period of positive results and pipeline updates, shares may pause as investors weigh the next set of catalysts.
Because the company announces frequent clinical and regulatory updates, daily price movements can reflect small shifts in sentiment as well as broader market conditions.
Nine-Month Financial Performance
Core operating profit increased 14% to $16.4 billion, and gross Margin was 82%. Reported earnings per share for the nine months were $5.62, up 10%. At actual exchange rates, nine-month total revenue growth was 8%, compared with 7% at constant exchange rates. Product revenue was $46,768 million, with alliance revenue growing 33% and collaboration revenue up 22%.
The Chief Financial Officer, Aradhana Sarin, explained that Investment is being directed to launches including Baxfendy and tozorakimab, while overall costs rose more slowly than revenue. Core selling, general and administrative expense was about 24% of total revenue, and costs rose more slowly than sales in the third quarter, supporting a wider margin. Management noted that double-digit growth in Oncology, Respiratory and Immunology and Rare Disease more than offset the effect of Patent expiries on some established medicines.
Pipeline and Approvals
The company reported 12 positive Phase III readouts so far this year and 47 approvals in major regions since its fourth-quarter 2025 results. These included first approvals for four new medicines, named Etcamah, Baxfendy, Klygefa and Amlypave.
First Phase III data were also delivered for three new molecular entities, tozorakimab, efzimfotase alfa and sonesitatug vedotin. Pascal Soriot, Chief Executive Officer, said the group is on track to deliver its 2030 ambition and sustain growth through the next decade.
Pipeline Scale
The pipeline includes about 180 projects, with 116 new molecular entities or major life-cycle management programmes in Phase II or Phase III. Of these, 20 new molecular entities are in the late-stage pipeline and 2 are under review, while 14 new molecular entities have been delivered against a target of 20 by 2030. A pipeline of this breadth spreads development across several therapy areas and technologies, which helps reduce dependence on any single programme.
Guidance for 2026
AstraZeneca reconfirmed its 2026 guidance at constant exchange rates. Total revenue is expected to increase by a mid-to-high single-digit percentage, and Core earnings per share is expected to increase by a low double-digit percentage. The Core tax rate is expected to be between 18% and 22%.
Management said multiple potential blockbuster Assets in late-stage development, together with new technologies scaling rapidly, support its confidence in sustaining growth through the next decade.
What to Watch Next
Areas to follow include further Phase III results, regulatory decisions for newly approved medicines, launch progress, the delivery of guidance for 2026 and the group's longer-term growth ambitions.
Conclusion
AstraZeneca PLC (LSE:AZN) eased 1.05% to 13,886.0p today. Its latest update showed nine-month revenue of $46.9 billion, Core earnings per share of $8.00 and a broad set of pipeline and regulatory milestones.
With guidance reconfirmed and a deep late-stage pipeline, attention remains on execution and clinical delivery.






Please wait processing your request...